Stock LINCOLN LINCOLN PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lincoln Pharmaceuticals Limited

Equities

LINCOLN

INE405C01035

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 11:00:47 14/05/2024 BST 		5-day change 1st Jan Change
584.9 INR +2.81% Intraday chart for Lincoln Pharmaceuticals Limited +0.46% -3.98%
03-30 Lincoln Pharmaceuticals Limited Announces Pirabhai Suthar Will Cease to Be an Independent Director CI
02-22 Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 4,206 4,251 2,676 4,494 6,230 6,784
Enterprise Value (EV) 1 4,582 4,352 2,262 3,578 5,095 5,666
P/E ratio 12.1 x 8.73 x 5.2 x 7.22 x 8.98 x 9.31 x
Yield 0.71% 0.71% 1.12% 0.67% 0.48% 0.44%
Capitalization / Revenue 1.17 x 1.16 x 0.69 x 1.06 x 1.32 x 1.33 x
EV / Revenue 1.27 x 1.19 x 0.59 x 0.84 x 1.08 x 1.11 x
EV / EBITDA 8.74 x 6.46 x 3.45 x 4.1 x 5.33 x 6.32 x
EV / FCF 398 x 15.8 x 5.38 x 7.62 x 75.2 x 54.6 x
FCF Yield 0.25% 6.33% 18.6% 13.1% 1.33% 1.83%
Price to Book 1.88 x 1.58 x 0.85 x 1.2 x 1.44 x 1.35 x
Nbr of stocks (in thousands) 20,000 20,000 20,000 20,000 20,030 20,030
Reference price 2 210.3 212.6 133.8 224.7 311.0 338.7
Announcement Date 05/09/18 04/09/19 08/09/20 07/09/21 06/09/22 06/09/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 3,606 3,662 3,865 4,242 4,721 5,103
EBITDA 1 524.2 674 655.1 872 956.3 895.8
EBIT 1 464.3 608 583.4 798 877 805.5
Operating Margin 12.87% 16.6% 15.09% 18.81% 18.58% 15.78%
Earnings before Tax (EBT) 1 462.5 621.9 672.3 837.2 959.4 1,005
Net income 1 346.2 487.1 514.4 622.2 693.6 729
Net margin 9.6% 13.3% 13.31% 14.67% 14.69% 14.29%
EPS 2 17.31 24.36 25.72 31.11 34.63 36.40
Free Cash Flow 1 11.52 275.4 420.6 469.4 67.77 103.8
FCF margin 0.32% 7.52% 10.88% 11.07% 1.44% 2.03%
FCF Conversion (EBITDA) 2.2% 40.86% 64.2% 53.83% 7.09% 11.59%
FCF Conversion (Net income) 3.33% 56.54% 81.76% 75.45% 9.77% 14.24%
Dividend per Share 2 1.500 1.500 1.500 1.500 1.500 1.500
Announcement Date 05/09/18 04/09/19 08/09/20 07/09/21 06/09/22 06/09/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 376 101 - - - -
Net Cash position 1 - - 414 916 1,136 1,118
Leverage (Debt/EBITDA) 0.7174 x 0.1491 x - - - -
Free Cash Flow 1 11.5 275 421 469 67.8 104
ROE (net income / shareholders' equity) 16.6% 19.7% 17.7% 18.1% 17.4% 15.6%
ROA (Net income/ Total Assets) 8.89% 10.7% 9.65% 11.8% 11.1% 8.98%
Assets 1 3,893 4,566 5,328 5,294 6,243 8,122
Book Value Per Share 2 112.0 135.0 157.0 188.0 216.0 251.0
Cash Flow per Share 2 3.280 2.730 6.120 5.720 9.390 2.520
Capex 1 99 149 76.9 87.5 455 143
Capex / Sales 2.75% 4.08% 1.99% 2.06% 9.64% 2.8%
Announcement Date 05/09/18 04/09/19 08/09/20 07/09/21 06/09/22 06/09/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
LINCOLN PHARMACEUTICALS LIMITED Stock Lincoln Pharmaceuticals Limited
-3.98% 136M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+31.06% 682B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.35% 586B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.42% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.02% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.27% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.53% 240B
NOVARTIS AG Stock Novartis AG
+10.16% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-8.14% 203B
AMGEN INC. Stock Amgen Inc.
+8.12% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LINCOLN Stock
  4. Financials Lincoln Pharmaceuticals Limited